Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia
Gecacitinib Combined With Luspatercept in Patients With Myelofibrosis and Anemia: A Single-center, Prospective, Single-arm Study
This single-center, prospective, single-arm study aims to evaluate the efficacy and safety of gecacitinib combined with luspatercept in patients with myelofibrosis and anemia who have not previously received a Janus kinase inhibitor. Participants will receive oral gecacitinib and subcutaneous luspatercept.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Bing Han
- Telefoonnummer: 01065295027
- E-mail: hanbing_li@sina.com.cn
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 18 years or older.
- Confirmed primary myelofibrosis according to the 2016 World Health Organization diagnostic criteria, or post-polycythemia vera or post-essential thrombocythemia myelofibrosis according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment diagnostic criteria.
- Intermediate-2 or high-risk disease according to the Dynamic International Prognostic Scoring System (DIPSS) or DIPSS-plus, or intermediate-1-risk disease with hepatosplenomegaly that is unresponsive to existing treatment and requires treatment.
- No previous treatment with a Janus kinase inhibitor.
- Discontinuation of other myelofibrosis treatments, such as interferon or hydroxyurea, immunosuppressants, corticosteroids, and growth factors such as erythropoietin, for at least 2 weeks or 6 half-lives before study treatment.
- Splenomegaly, with the spleen palpable 5 cm below the left costal margin.
- Hemoglobin below 100 g/L, with or without red blood cell transfusion dependence.
- Platelet count of at least 75 × 10^9/L.
- Absolute neutrophil count of at least 1.0 × 10^9/L.
- Peripheral blood blasts of 10% or less.
- Eastern Cooperative Oncology Group performance status of 0-2 and a life expectancy of more than 6 months.
- Ability to independently provide written informed consent.
Exclusion Criteria:
-
Clinically significant anemia associated with iron, vitamin B12, or folate deficiency; autoimmune or hereditary hemolytic anemia; gastrointestinal bleeding; or thalassemia.
-
Active infection.
-
A history of malignancy within the previous 5 years, except for cured basal cell carcinoma of the skin or cervical carcinoma in situ.
-
Significant hepatic or renal dysfunction, or dysfunction of another major organ.
-
Other serious conditions that, in the investigator's judgment, may affect participant safety or compliance, including:
- Uncontrolled diabetes mellitus, with blood glucose above 250 mg/dL or 13.9 mmol/L.
- Hypertension that cannot be controlled to a systolic blood pressure below 160 mmHg and a diastolic blood pressure below 100 mmHg despite combination antihypertensive treatment.
- Peripheral neuropathy of grade 2 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.
-
Previous splenectomy.
-
Previous treatment with any transforming growth factor-beta ligand inhibitor.
-
Pregnancy or breastfeeding, women planning pregnancy during the study, or men with near-term plans to father a child.
-
Suspected hypersensitivity to gecacitinib, luspatercept, or drugs of the same class.
-
Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Gecacitinib + Luspatercept
gecacitinib 100 mg orally twice daily, combined with luspatercept at an initial dose of 1.0 mg/kg subcutaneously every 3 weeks |
Gecacitinib will be administered orally at 100 mg twice daily in the fasting state. Dose adjustments will be based primarily on platelet counts and absolute neutrophil counts. Gecacitinib will be interrupted if the platelet count falls below 50 × 10^9/L and may be resumed when the platelet count recovers to at least 50 × 10^9/L. Luspatercept will be administered by subcutaneous injection at an initial dose of 1.0 mg/kg every 3 weeks. The dose may be adjusted according to blood counts, up to a maximum of 1.75 mg/kg. Treatment may be interrupted if the predose hemoglobin level is at least 120 g/L or if hemoglobin increases rapidly by more than 20 g/L. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Participants Achieving an Anemia Response
Tijdsspanne: 24 week
|
Anemia response is defined as conversion from red blood cell transfusion dependence at baseline to transfusion independence, or an increase in hemoglobin of at least 20 g/L in participants who do not require red blood cell transfusions and have a baseline hemoglobin level of 100 g/L or lower. |
24 week
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Participants With a Sustained Increase in Mean Hemoglobin of at Least 1.0 g/dL Without Transfusion
Tijdsspanne: 24 week
|
Percentage of participants achieving an increase in mean hemoglobin of at least 1.0 g/dL from baseline for at least 12 consecutive weeks without red blood cell transfusions. |
24 week
|
|
Time to Anemia Response
Tijdsspanne: week 24
|
Time from the first dose of study treatment to the first documented anemia response. |
week 24
|
|
Duration of Anemia Response
Tijdsspanne: week 24
|
The longest continuous duration of anemia response among participants who achieve an anemia response. |
week 24
|
|
Change From Baseline in Red Blood Cell Transfusion Amount and Frequency
Tijdsspanne: week 24
|
Changes from baseline in the amount and frequency of red blood cell transfusions during study treatment. |
week 24
|
|
Change From Baseline in Hemoglobin
Tijdsspanne: weeks 4, 8, 12, 16, 20, and 24
|
Change in hemoglobin concentration, measured in g/L, from baseline at scheduled treatment-period visits. |
weeks 4, 8, 12, 16, 20, and 24
|
|
SVR35
Tijdsspanne: week 12 and 24
|
Percentage of participants achieving a reduction in spleen volume of at least 35% from baseline. |
week 12 and 24
|
|
DoMSR
Tijdsspanne: week 24
|
Time from the first documented reduction in spleen volume of more than 35% from baseline to the first subsequent assessment showing a reduction of less than 35% from baseline. |
week 24
|
|
MPN-SAF TSS
Tijdsspanne: weeks 4, 8, 12, 16, 20, and 24
|
Percentage of participants achieving a reduction of at least 50% from baseline in the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS). |
weeks 4, 8, 12, 16, 20, and 24
|
|
Reduction in Fatigue Score
Tijdsspanne: week 24
|
Percentage of participants achieving a reduction of at least 50% from baseline in fatigue symptom score. |
week 24
|
|
Adverse Events
Tijdsspanne: From the first dose through 28 days after the last dose.
|
Incidence and severity of adverse events, including events that develop or worsen during treatment and events occurring after treatment that are considered related to the study drugs by the investigator. Serious adverse events and adverse events leading to treatment interruption or discontinuation will also be recorded. |
From the first dose through 28 days after the last dose.
|
|
PFS
Tijdsspanne: 12 month
|
Time from the first dose of study treatment to disease progression or death from any cause, whichever occurs first. |
12 month
|
|
OS
Tijdsspanne: 12 month
|
Time from the first dose of study treatment to death from any cause. |
12 month
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- K11529
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .